Furthermore, the sensitivity of melanoma cells to ferroptosis has been linked to their dedifferentiation status, with dedifferentiated cells being more susceptible to ferroptosis, suggesting a potential for combined treatment with BRAF inhibitors and ferroptosis inducers (211). This evidence concerns the gene BRAF and melanoma.